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Lisa A. Palmer,1 George E. Sale,2 John I. Balogun,1 Dan Li,1 Dan Jones,3 Jeffrey J. Molldrem,1
Rainer F. Storb,2 Qing Ma1Allogeneic bone marrow transplantation (BMT) is an effective therapy for hematologic malignancies. How-
ever graft-versus-host disease (GVHD) is a major limiting factor for a successful patient outcome. GVHD is
a result of alloimmune responses of donor T lymphocytes attacking the recipient’s cells and tissues. Chemo-
kine receptor CCR5 plays a role in solid organ allograft rejection and mediates murine GVHD pathogenesis.
Herein, we report that infiltrating lymphocytes in the skin of human acute GVHD (aGVHD) samples are pre-
dominantly CCR51 T cells. In addition, we characterized the features of the CCR5 expression on alloreac-
tive T lymphocytes. We found that the CCR51 population exhibits the characteristics of the activated
effector T cell phenotype. CCR5 expression is upregulated upon allogenic stimulation, and CCR51 cells
are proliferating with coexpression of T cell activation markers. Furthermore, the activated T cells producing
inflammatory cytokine tumor necrosis factor (TNF)a, interleukin (IL)-2, or interferon (IFN)-g, are positive
for CCR5. Thus, CCR5 is a marker for GVHD effector cells and CCR51 T cells are active participants in the
pathogenesis of human aGVHD.
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Graft-versus-host disease (GVHD) is the major
cause of morbidity and mortality in allogeneic hemato-
poietic cell transplantation (HCT) recipients because
of alloimmune responses [1]. The disease is character-
ized primarily by targeted epithelial cell injury in skin,
intestines, and liver [2-4]. The development of GVHD
is thought to involve 3phases:T cell activation, followed
by proliferation and differentiation of allogeneic T cells
into activated effector cells, and finally specific tissue
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6/j.bbmt.2009.12.002lymphocytes, although their precise phenotype remains
elusive. Current evidence suggests that GVHD repre-
sents a systemicThelper (Th)1 type response: this char-
acterization includes a CD4 response of Th1 type,
resulting inCD8 cytotoxicT lymphocyte (CTL) gener-
ation and an inflammatory cytokine cascade [6].
Chemokines and their receptors play an important
role in regulating leukocyte migration and activation
[7]. Recently, the functional state of T cells has been
characterized by the chemokine receptor expression
pattern [7-9]. In particular, chemokine receptor
CCR5 is a marker for effector T cells. CCR5 is a core-
ceptor for HIV entry and has been studied extensively
[10]. The expression of CCR5 is very low on naı¨ve T
cells, but is highly upregulated on both CD41(Th1)
T cells and activated antigen-specific CD81 T cells
[11,12]. The function of CCR5 and its ligands in
GVHDhas been primarily explored in murine models.
It has been reported that CCR51/CD81T cells medi-
ate hepatic injury in mouse GVHD and blocking anti-
body to CCR5 reduces the damage [13]. In addition,
MIP-1a, 1 of the ligands for CCR5, has also been
shown to mediate mouse GVHD [14,15]. Although 2
groups demonstrated that genetic deletion of CCR5
in the donor can reduce acute GVHD (aGVHD) in
mice [16,17]; others reported that CCR52/2 or MIP-
1a2/2 donor T cells accelerate GVHD in the liver
and lung [17,18]. These data suggested that the role
of CCR5 in alloimmmune responses is complicated,311
Figure 1. Infiltrating T cell lymphocytes in human aGVHD tissues are predominantly CCR51. (A) Skin and lip biopsies of GVHD patients. Three ad-
jacent sections of skin (top panel) and lip (lower panel) biopsies of a representative GVHD patient were stained with H&E, CCR5 antibody, or CD3
antibody. CCR51 and CD31 lymphocyte infiltrates were found in both the dermal and epidermal layers. (B) Lip biopsy of a representative GVHD patient
with damaged salivary gland. Right and left panels are adjacent sections stained with CCR5 or CD3 antibodies. In each panel, the right side is an enlarged
picture of the area with the arrow. CCR51 and CD31 lymphocyte infiltrates were found in the damaged area of salivary gland.
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pretransplant conditioning-dependent fashion in mu-
rine GVHD models [17]. In addition to T cells, other
cell types such as dendritic cells (DCs) and B cells are
involved in the pathogenesis of GVHD [19,20]. CCR5
has been shown to express on DCs and specifically the
dermal Langerhans cells [21,22]. Langerhans cells rep-
resent the specialized DCs of the epidermis, and play
an important role in skin GVHD [19]. Clearly, the
role of CCR5 is intricate and complicated, and the
field is as of yet still unresolved regarding the role of
CCR5 in human GVHD.
It has been shown that infiltrationofCCR51Tcells
occurs in both the acute and chronic phases of human
renal allograft rejection [23]. A large cohort of patients
genetically lacking CCR5 (CCR5D32) demonstrated
the functional importance of CCR5 in human renal
allograft survival [24]. Recently, we have identified
donors genetically lacking CCR5 and these donorswere correlated with the outcome of patients who re-
ceived major histocompatibility complex (MHC)-
matched unrelated HCT [25]. We found a decreased
incidence of GVHD in the absence of CCR5 on donor
T cells. In this study, we report that lymphocyte infil-
trates at the skin sites of human aGVHD are predomi-
nantly CCR51 T cells, including both CD41 and
CD81 subsets.Upon allogeneic stimulation, themajor-
ity ofCCR51 cells demonstrated characteristics of acti-
vated proliferating T cells with coexpression of
activation marks and production of inflammatory
cytokines.MATERIALS AND METHODS
Immunohistochemistry
Skin and lip biopsies were retrieved from the
GVHD tissue repository at the Fred Hutchinson
Figure 2. Infiltrating CCR51 T cell lymphocytes in the skin of aGVHD are both CD41 and CD81 T cells. The skin biopsies of a representative GVHD
patient were double stained with CCR5 antibody and either CD4 antibody (top panel) or CD8 antibody (bottom panel). On the right side, CCR51 cells
are brown, and both CD41 and CD81 cells are Texas-Red. The same slides were photographed by light (right panel) and fluorescence microscopy (left
panel) for Texas-Red.
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tween 1988 and 2000 [25,26]. Formalin-fixed paraffin-
embedded sections of skin and lip were examined by
hematoxylin and eosin stain, and CD3, CD4, CD8,
CCR5, CD1a, and CD20 immunostains performed
using avidin-biotin conjugated reagents. The coex-
pression of CCR5 in combination with CD4 or CD8
was performed using DAKO Envision Double System
(DAKO System) that can detect 2 antigens from the
same species within 1 specimen. The skin biopsies
were double stained with CCR5 antibody and either
CD4 or CD8 antibodies (Texas-Red). The same slides
were photographed by light and fluorescence micros-
copy for Texas-Red.
Dendritic Cell Culture
Peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coat preparations derived
from whole blood of healthy volunteer donors (Gulf
Coast Regional Blood Center, Houston, TX). The
buffy coat was diluted with phosphate-buffered saline
(PBS) at a 1:2 ratio and centrifuged over Histopaque-
1077 (Sigma Diagnostics, St. Louis, MO) for 30 min-
utes. The PBMC interface was collected and analyzed
for purity by flow cytometry and frozen for future use.
DCs were generated from CD14-positive selected
monocytes using magnetic beads (Miltenyi Biotec,
Gladbach, Germany). The CD14-positive fraction
was cultured in RPMI plus 50 ng/mL granulocyte
macrophage colony-forming unit (GM-CSF) and 10
ng/mL interleukin (IL)-4. On day 6, 1/100 dilution
of maturation cytokine factor 100 PITIP (1 mg/mL
Poly [cytidylic-inosinic] acid, 1 mg/mL IL-1b, 1 mg/
mL tumor necrosis factor (TNF)-a, 1.5 mg/mL IL-6,100 mg/mL Prostaglandin E2) was added to the differ-
entiation culture as described [27]. DCs were collected
on day 9 of culture.Mixed Lymphocyte Reaction
Frozen PBMCs from healthy volunteer donors
were thawed and cultured in RPMI plus 10% fetal
bovine serum (FBS) and 1% streptomycin/penicillin.
After 24 hours, the cells were counted and resuspended
to 1  106 cells/mL and labeled either responder or
stimulator. This day is labeled day 0, and cells were
assayed on day indicated in figure legends. The
responders were mixed in a 1:1 ratio with irradiated
stimulator (allogeneic) or irradiated responders (autol-
ogous) mixed lymphocyte reaction (MLR), respec-
tively. Where indicated, the MLR was carried out
using DCs; allogeneic or autologous DC MLR was
performed using a DC:PBMC ratio of 1:100. Cells
were collected and stained on days 3, 6, 9, and/or day
12, as indicated in figure legends.Intracellular Cytokine Assay
The intracellular cytokine staining was carried out
as previously described [28]. In brief, the MLR cul-
tures were treated on the indicated day with Brefeldin
A (final concentration of 10 mg/mL) for 5 hours at
37C. Cells were then collected, washed, and stained
for surface expression of CD4, CD8, and CCR5. Cells
were washed and permeabilized using BD FACS Per-
meabilizing Solution 2 (BD Biosciences, San Jose,
CA) for 10 minutes with occasional mild vortex. Cells
were washed and stained for intracellular cytokines
Figure 3. Strong CCR5 expression on T cells but not dendritic cells in aGVHD tissues. Immunohistochemistry was performed on paraffin sections for
CCR5 (left panel) and Langerhans DC marker CD1a (right panel). Top panel: skin biopsy with CCR51 T cells in the superficial dermis (arrows) and
epidermis in addition to CD1a1 Langerhans DCs at sites of lymphocytic infiltration. Middle panel: foci of epidermal damage with high-level CCR5 ex-
pression in T cells (arrow) but weak CCR5 staining in CD1a1 Langerhans DCs. Bottom panel: lip biopsy from a case with minimal epithelial damage and
no detectable CCR5 expression in CD1a1 Langerhans DCs.
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Figure 4. CCR5 is coexpressed with T cell activation markers. Mixed lymphocyte culture (MLR) were used to activate PBMC from normal donors with
allogenic DCs mixed with responder PBMCs (DC-MLR) at a DC:PBMC ratio of 1:100. The cells were collected 7 days after stimulation and stained with
antibodies CD4, CD8, CCR5, and a panel of activation markers including CD45RA, CD45RO, CD62L, and CD69. The representative dot plots of CD4
(upper panel) and CD8 (lower panel) T cells demonstrated the coexpression of CCR5 and activation marks. Data were representative of experiments
from 3 independent samples. Cells were collected on a FACscaliber Flow Cytometer and data was analyzed by Cell Quest software (Becton Dickinson).
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IL-2, and inteferon (IFN)-g (BD Biosciences).RESULTS
Infiltrating T Cell Lymphocytes in the Skin of
Human aGVHDAre Predominantly CCR51
Cells
Based on our recent report, patients who received
bone marrow (BM) from CCR5D32 homozygous do-
nors had lower risk of skin GVHD than the control
group, with an odds ratio of 0.19 and 95% confidence
interval of 0.05-0.80 and the difference is statistically
significant (P 5 .02) [25]. This implicated CCR5 ex-
pression might mediate the invasion of lymphocytes
into the skin, liver, and gut, which is the characteristic
feature of GVHD [6]. We therefore examined the de-
gree of expression of CCR5 in the lymphocytes in the
skin of human aGVHD.We screened our GVHD tis-
sue repository of allograft recipients, to select 10 sam-
ples from skin and lip that showed histologic features
of aGVHD (epithelial apoptosis associated with lym-
phocyte infiltration) and had the most abundant num-
ber of lymphocytes. Samples were stained with CCR5,
CD3, CD4, and CD8 antibodies.
As shown in Figure 1A, a representative example of
GVHD skin (top panel) and lip (lower panel), lympho-
cytes were found near the dermal and epidermal junc-
tions, and were concentrated in the basal layer.
Adjacent sections that were stained with CCR5antibody or CD3 antibody showed a similar pattern.
Figure 1B is a representative example of the lip biopsy
of a GVHD patient: the salivary gland was damaged
by lymphocytes, which resulted in the dry mouth
symptoms often seen in GVHD patients. The pattern
of CCR5 antibody staining in these lip biopsies is
similar to that of CD3 staining, suggesting that the
gland-infiltrating lymphocytes were CCR51 T cells.
To determine whether the CCR51 T cells were
CD41 versus CD81, we examined the coexpression of
CCR5 in combination with CD4 or CD8, using the
DAKO Envision Double System that can detect 2 anti-
gens from the same species within 1 specimen. As shown
in Figure 2, themajority of infiltrating cells were double
stained with either CD4 or CD8 and CCR5. Thus,
CCR5 expression is present on the majority of both
CD41 and CD81 T cells involved in skin GVHD.
In addition, we examined all 10 skin and lip biop-
sies for Langerhans DC marker CD1a and B cell
marker CD20. No CD201 B cells were noted (data
not shown) and CD1a1 epidermal Langerhans cells
were abundant in 5 samples. The samples with heavy
Langerhans cell infiltrates were retrieved for CCR5
staining. Representative sections are shown inFigure 3.
In the top panel, the skin biopsy with extensive epider-
mal damage has CCR5 expression on the vast majority
of T cell infiltrates in the superficial dermis (arrows)
and epidermis, with increased CD1a1 Langerhans
DCs at sites of lymphocytic infiltration. The foci of
epidermal damage has high-level CCR5 expression
on T cells, but weak to minimal CCR5 staining on
Figure 5. CCR5 is upregulated on proliferating T cell lymphocytes following allogeneic activation. Responder PBMCs were incubated in CFSE for 10
minutes and then washed with PBS for coculture with allogenic DCs. Cells were collected 9 days after stimulation and stained with CD4 and CD8 an-
tibodies. The gated lymphoblast population of CD41 or CD81 T cells were analyzed separately for CCR5, CCR7, and CXCR3 expression. Data shown
here are representative of 3 independent samples.
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lip biopsy from a case with minimal lymphoid infiltrate
or epithelial damage shows no detectable CCR5 ex-
pression on CD1a1 Langerhans DCs. Thus, strong
CCR5 expression is present on T cells but not DCs
in the skin of aGVHD.CCR5 Is Expressed on Activated T Cells and
Upregulated on Proliferating T Lymphocytes
following Allogeneic Activation
To dissect the human alloimmune responses medi-
ated by CCR51 T cells, we used MLR with allogeneic
DCsmixed with responder PBMCs for lymphocyte ac-
tivation and proliferation. We found that the expres-
sion level of CCR5 on both the CD41 and CD81 T
cells increased from day 3 and peaked at days 6-9 after
allogeneic MLR (data not shown). We further exam-
ined the characteristics of the CCR51 T cells after al-
logeneic MLR. As shown in Figure 4, the majority of
CCR51 were CD45RA2/CD45RO1 with decreased
expression of CD62L and CD69, representing the ac-
tivated T cell phenotype. Furthermore, we examinedwhether the CCR51 population was actively prolifer-
ating. CFSE (carboxy fluorescein succinimidyl ester)-
labeled responder cells were plated with stimulator
cells and cell proliferation was measured by CFSE in-
tensity with FACS. As shown in Figure 5, the prolifer-
ating CD41 and CD81 T cells with low CFSE
staining were positive for CCR5. Thus, the expression
of CCR5 is greatly restricted to the proliferating T
lymphocytes. In contrast, both CCR7 and CXCR3
do not appear to have the same restriction to prolifer-
ating cells as CCR5.CCR51 T Cells Produce Cytokine TNFa, IL-2,
and IFN-g
The mechanism of GVHD has been described as
a ‘‘cytokine storm’’ because of the central role of cyto-
kines in mediating tissue injury and inflammation
characteristic of GVHD pathology [6]. Therefore,
we assessed whether cells producing the cytokine
TNFa, IL-2, and IFN-g were positive for CCR5.
Cells were treated with brefeldin A 7 days post-MLR
and were stained for CD4, CD8, and CCR5. The
Figure 6. CCR51 T lymphocytes and intracellular cytokine production of TNFa, IL-2, and IFN-g. Allogenic DCs mixed with responder PBMCs (DC-
MLR) at a DC:PBMC ratio of 1:100. The MLR cultures were treated with brefeldin-A on day 7 for 5 hours. The cells were harvested and stained with
CD4, CD8, CCR5, and intracellular cytokines TNFa (top panel), IL-2 (middle panel), and IFN-g (bottom panel). The left panel of A (CD4) and B (CD8)
were the representative dot-plots of intracellular cytokine production and the gated cells were positive for the cytokine using autologous MLR sample as
the reference. The right panel of A and B was the CCR5 expression of the gated cells from the respective upper panel, and the quadrant gates were
decided based on isotype control. Results were representative of 4 independent samples.
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staining with antibodies against TNFa, IL-2, or
IFN-g. As shown in Figure 6 (top panel), the CD41
(A) or CD81 (B) T cells producing intracellular
TNFa were gated and analyzed for CCR5 expression.
The majority of TNFa producing cells were positive
for CCR5, with about 80.5% for CD41 and 79.9%
for CD81 T cells, respectively. We found a similar
pattern of CCR5 expression in IL-2 producing cells
(Figure 6, middle panel). The majority of IFN-g pro-
ducing cells (74.5%) were positive for CCR5 in the
CD41 T cell population, whereas only about 56.9%
were positive for CCR5 in the CD81T cell population
(Figure 6, bottom panel). In conclusion, CD41T cells
that produce cytokine TNFa, IL-2, or IFN-g, were
expressing CCR5. However, CCR5 expression was
only detected on TNFa or IL-2 producing CD81 T
cells and about half of IFN-g producing CD81T cells
were negative for CCR5 expression.DISCUSSION
In the current study, we investigated the role
of chemokine receptor CCR5 in skin GVHD and
alloimmune responses. We demonstrated that CCR5
expression is present on both CD41 and CD81 T
cell infiltrates in the skin biopsies of human aGVHD.
CCR5 is upregulated upon allostimulation and ex-
pressed on activated T cells. In addition, the expres-
sion of CCR5 is restricted to the proliferating T
lymphocytes. Furthermore, we found that activated
T cells producing cytokine TNFa, IL-2, or IFN-g
are positive for CCR5. Together, our data indicated
that CCR5 expression on T cells mediates allo-
immune responses in GVHD.
CCR5 is considered 1 of the ‘‘inflammatory’’ che-
mokine receptors regulated by proinflammatory stim-
uli to orchestrate immune responses, in comparison
with the ‘‘homeostatic ‘‘ group, which are important
in immune surveillance such as CCR7. Inflammatory
318 Biol Blood Marrow Transplant 16:311-319, 2010L. A. Palmer et al.chemokine receptors are upregulated during tissue
damage or inflammation, and involved in T cell polar-
ization [29-31]. Gene expression profiles have shown
that CCR5 was upregulated during aGVHD in human
[32,33]. Our data further demonstrated that CCR5 ex-
pression is on activated and proliferating T cells upon
allogeneic stimulation. In contrast, CCR7 was found
within both proliferating and nonproliferating T cells,
and there was no significant increase in the expression
of CCR7. Interestingly, CXCR3, another inflamma-
tory chemokine receptor, does not show the same re-
striction to proliferating cells as CCR5. Although
almost all proliferating T cells were positive for
CXCR3, there was a high percentage of nonproliferat-
ing T cells expressing this chemokine receptor. Thus,
the data suggests a critical role of CCR5 expression in
alloimmune responses and GVHD.
We and others have demonstrated that the protec-
tive effect of the CCR5 deletion mutation in GVHD
[25,34]. In a small cohort study, we found that in the
absence of CCR5 on donor cells, there is a decreased
incidence of GVHD and increased relapse rate in re-
cipients with HLA-matched unrelated marrow donors
[25]. In particular, there is a significant reduction of
skin GVHD.We further examined the skin and lip bi-
opsies from aGVHD patients for CCR5 expression in
situ, and found the majority of infiltrating T cells were
positive for CCR5. Altogether, these data confirms
that CCR5 expression plays an important role in medi-
ating human GVHD.
CCR5 is highly upregulated on both CD41(Th1) T
cells andactivated antigen-specificCD81Tcells [11,12].
Using an intracellular cytokine assay, we found that acti-
vatedCD41Tcells that produce inflammatory cytokine
TNFa, IL-2, or IFN-g, were positive for CCR5. In ad-
dition, the TNFa and IL-2-producing CD81 T cells
also expressed CCR5. This observation supported the
notion thatCCR5 is amarker for effectorT cells that ac-
tively participate in the ‘‘cytokine storm’’ of GVHD [6].
Chemokines and their receptors are important in
many human diseases, including HIV, autoimmune dis-
ease, inflammatory disease, and organ graft rejection
[35]. Currently, small molecule antagonists and human-
izedmonoclonal antibodies (mAbs) targeting chemokine
receptors are developed by industry and tested in pre-
clinical models as well as in phase I trials [36-39]. Our
data demonstrated that CCR51 T cells are important
in mediating GVHD in humans. The results will pro-
vide rationale to develop novel treatment for GVHD.ACKNOWLEDGMENTS
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